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Abstract
Nonalcoholic fatty liver disease/nonalcoholic steato-
hepatitis (NAFLD/NASH) is a challenging and multisystem 
disease that has a high socioeconomic impact. NAFLD/
NASH is a main cause of macrovesicular steatosis and 
has multiple impacts on liver transplantation (LT), on 
patients on the waiting list for transplant, on post-
transplant setting as well as on organ donors. Current 
data indicate new trends in the area of chronic liver 
disease. Due to the increased incidence of metabolic 
syndrome (MetS) and its components, NASH cirrhosis 
and hepatocellular carcinoma caused by NASH will soon 
become a major indication for LT. Furthermore, due to an 
increasing incidence of MetS and, consequently, NAFLD, 
there will be more steatotic donor livers and less high 
quality organs available for LT, in addition to a lack of 
available liver allografts. Patients who have NASH and 
are candidates for LT have multiple comorbidities and are 
unique LT candidates. Finally, we discuss long-term grafts 
and patient survival after LT, the recurrence of NASH 
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and NASH appearing de novo  after transplantation. In 
addition, we suggest topics and areas that require more 
research for improving the health care of this increasing 
patient population. 
Key words: Nonalcoholic steatohepatitis; Chronic liver 
disease; liver transplantation; Nonalcoholic fatty liver 
disease; Outcome
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Core tip: Nonalcoholic fatty liver disease/nonalcoholic 
steatohepatitis (NAFLD/NASH) is a challenging and 
multisystem disease that has a high socioeconomic 
impact. NAFLD/NASH is a primary cause of macro-
vesicular steatosis and has several impacts on liver 
transplantation (LT), which is transmitted to transplant 
recipients and organ donors. Current data indicate a 
new trend in the area of chronic liver disease. Due to 
the increased incidence of metabolic syndrome (MetS) 
and its components, NASH cirrhosis and hepatocellular 
carcinoma caused by NASH will soon become a major 
indication for LT.
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INTRODUCTION
Parallel to the increasing prevalence of diabetes 
mellitus type 2 (T2DM) and obesity and a close 
relationship with insulin resistance (IR) and metabolic 
risk factors, nonalcoholic fatty liver disease (NAFLD) 
has become the most common chronic liver disease 
(CLD) in the world over the past 30 years, with 
an estimated prevalence of 10%-40%[1,2]. NAFLD 
is characterized by increased fat depositions in 
the liver with clinical-histological phenotypes that 
range from a simple steatosis (present in > 5% of 
hepatocytes, as shown in histological analysis or 
magnetic resonance spectroscopy) to nonalcoholic 
steatohepatitis (NASH). NASH is a more aggressive 
form of the disease and includes a histological 
presentation of steatosis, ballooning hepatocytes and 
lobular inflammation that leads to advanced fibrosis 
and, finally, cirrhosis and hepatocellular carcinoma 
(HCC)[1,3]. Given the growing prevalence of NAFLD, 
several studies have attempted to determine the 
clinical course and progression of the disease, but the 
exact prognosis remains unclear. A recently published 
Swedish retrospective study was the largest biopsy-
proven NAFLD study to provide insight on the long-
term prognosis and outcomes of the disease, with a 
follow-up period of up to 40 years[4]. In that report, 
NAFLD patients had an increased risk for mortality 
and liver-related morbidity (12% of the patients 
developed severe liver disease, which is defined as 
liver failure, compensated or decompensated liver 
cirrhosis and HCC). Interestingly, the presence of 
NASH did not significantly increase the risk for liver-
related morbidity or overall mortality. The fibrosis 
stage was highly predictive of the risk of developing 
sever liver disease, with a hazard ratio that ranged 
from 1.9 in F0 to 104.9 in F4. The primary high fibrosis 
stages (F3-F4) predicted overall mortality[4], which is 
similar to previous published research[5,6]. Compared 
to other etiologies of chronic liver disease, NAFLD has 
a slower fibrosis progression, with an estimated time 
for developing severe liver disease at 22-26 years for 
F0-1, 9.3 years for F2, 2.3 years for F3 and 0.9 years 
for F4 (for decompensation)[4]. The clinical burden 
of NAFLD extends beyond the liver, with evidence 
indicating that NAFLD is a multisystem disease that is 
closely related to cardiovascular disease (CVD), chronic 
kidney disease (CKD) and T2DM. It is still not clear 
whether NAFLD is only a risk factor or is an important 
component of the pathophysiological mechanisms in 
the development and progression of those diseases[7]. 
In addition, a major cause of morbidity and mortality 
in NAFLD patients is CVD, followed by malignancies 
and liver-related diseases (cirrhosis and HCC) as the 
third cause[7]. HCC is the sixth most common cancer 
in the world that is predisposed with the presence 
of cirrhosis, but emerging data suggest that HCC 
can evolve in non-cirrhotic NAFLD and is strongly 
associated with metabolic syndrome (MetS)[8]. The 
HCC that is associated with NAFLD/NASH has a distinct 
phenotype. It is often diagnosed at an older age and in 
the advanced stages of liver disease, and, compared 
with the HCC in viral hepatitis, is less aggressive and 
therefore more commonly missed on routine scans for 
malignancies[9]. With the continuous increase in the 
incidence of obesity, T2DM and MetS in United States 
(US) and Europe, it is predicted that NAFLD/NASH 
will become the most common cause of HCC in the 
Western world. NAFLD/NASH has already become 
the second leading cause of liver transplantation (LT) 
in the US and, importantly, the number of patients 
who have NAFLD/NASH and are on the waiting list 
for transplantation increased by 170% from 2004 to 
2013. Thus, end-stage liver disease (ESLD) due to 
NAFLD/NASH will become the most common indicator 
for LT in the near future[10]. 
We expect groundbreaking changes in the area 
of LT. Therefore, this review discusses the multiple 
impacts of NAFLD on LT. First, due to the aging of the 
population and an increasing incidence of MetS and 
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its liver manifestation (i.e., NAFLD/NASH), ESLD as a 
consequence of NASH will become a primary driver 
of LT in the near future. Furthermore, due to the 
increasing incidence of obesity, and, consequently MetS, 
the prevalence of NAFLD in the population will also 
increase[1,2] As such, owing to the growing incidence of 
NAFLD, we can expect that there will be more steatotic 
donor livers and fewer high quality organs available 
for LT. Therefore, NAFLD affects both the demand 
for LT and the supply of available donors.Moreover, 
patients who have NASH and are candidates for LT have 
several comorbidities, such as obesity, T2DM and other 
MetS components, as well as CVD and CKD. These 
patients are uniquely challenging LT candidates, and 
transplantation specialists are continuously exposed to 
the challenges of transplantation from obese donors, 
as well as the NASH recipients with their often multiple 
comorbidities. Finally, we discuss long term grafts and 
patient survival after LT, the recurrence of NASH and 
NASH appearing de novo after transplantation[11,12] 
Figure 1. In addition, we suggest topics and areas 
for further research for improving health care for this 
increasing patient population. 
For this Review, we identified references using 
PubMed and the terms “NAFLD”, “NASH”, and “liver 
transplantation.” We only reviewed articles that were 
published in English. The references were selected 
based on originality and their relevance to the domain 
of this Review.
NAFLD RELATED END-STAGE LIVER 
DISEASE AND HCC AS INDICATIONS 
FOR LIVER TRANSPLANTATION
NAFLD patients can necessitate the need for LT in two 
primary ways: developing cirrhosis that manifests with 
decreased synthetic/excretion function(s) and signs 
of portal hypertension and HCC development. It is 
estimated that approximately one-third of the current 
population in industrialized countries has NAFLD as a 
consequence of the liver’s involvement in the context 
of MetS. As mentioned above and according to many 
authors, it is clear that over the next ten or twenty 
years, the prevalence of NAFLD will increase due to the 
epidemic rise in obesity, T2DM, arterial hypertension 
and the prevalence of MetS, as well as people living 
longer[10-13]. Consequently, NAFLD-related liver disease 
is currently the most rapidly increasing indication 
for LT in the US, and it is anticipated that NAFLD-
related liver disease will become the leading indication 
for LT in the near future[14,15]. In the context of the 
increasing incidence of NAFLD as an indication for LT, 
it is important to highlight several facts. First, due to 
the development of direct antiviral agents (DAA) for 
hepatitis C (HCV), the incidences of cirrhosis and HCC 
due to HCV as indications for LT will decrease over time. 
Three years ago, Wong et al[10] analyzed the United 
Network for Organ Sharing and Organ Procurement 
and Transplantation Network’s (UNOS/OPTN) registry 
data from 2004 to 2013. There were four groups of 
registrants who were on the liver transplant waitlist: 
patients who had an HCV infection, NASH, alcoholic 
liver disease (ALD), or a combination of HCV infection 
and ALD. Over a period of nine years, the numbers of 
new patients on the waitlist who had NASH, ALD, and 
HCV increased by 170%, 45% and 14%, respectively. 
Moreover, the percentage of registrants who had HCV 
and ALD decreased by 9% (from 880 to 803)[10].
A recent study by Goldberg et al[16] analyzed the 
prevalence of HCV from 2010 to 2014 from National 
Health and Nutrition Examination Survey (NHANES) 
data. They also collected data from patients who had 
cirrhosis and chronic liver failure (LF) from 2006 to 
2014 and were in the Health Core Integrated Research 
Database. In addition, they analyzed data from liver 
transplant recipients from UNOS from 2003 to 2015. 
By combining data from these three databases, the 
study investigated current changes in liver disease(s); 
HCV, alcoholic liver disease (ALD) and NAFLD/NASH 
through the course of liver disease; CLD - compensated 
cirrhosis, decompensated cirrhosis and HCC; and the 
waiting list for LT and LT recipients. The study authors 
found that there were significant changes in CLD 
etiology that were associated with important alterations 
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post-lT reccurent NAFlD 
de novo  NAFlD 
CVD; CKDpre-lT related 
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Figure 1  Higher incidence of metabolic syndrome and its complications 
leads to a higher incidence of nonalcoholic steatohepatitis/nonalcoholic 
fatty liver disease and, consequently, to more patients who have end-
stage liver disease. At the same time, due to MetS and its components, we will 
have more steatotic livers, i.e., more organs of lower quality that are available 
for LT. Therefore, in the future, since NAFLD will affect both the demand for 
LT and the supply of available organs. Patients who have NASH and are 
candidates for LT have several comorbidities and are unique LT candidates. 
Post-LT, there are several challenging issues for NAFLD: recurrent NAFLD, 
de novo NAFLD and the risk for CVD and CKD. MetS: Metabolic syndrome; 
NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; 
ESLD: End-stage liver disease; LT: Liver transplantation; CVD: Cardiovascular 
diseases; CKD: Chronic kidney disease.
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signs of liver cirrhosis or advanced fibrosis. According 
to recent research, NAFLD patients who have not 
developed cirrhosis have a risk of developing HCC; 
however, there are no studies that examine the cost-
benefit of screening in this population of patients. 
However, the current data on the increasing incidence 
of NAFLD combined with the growing incidence of 
MetS and NAFLD in young people indicate that there 
will be a need for LT in the context of NAFLD related 
decompensated cirrhosis and NAFLD related HCC[13,20,21].
Due to the substantial increase in the proportion 
of transplants due to NAFLD, as well as new waitlist 
registrants with NAFLD cirrhosis complications, NAFLD/
NASH cirrhosis and related HCC are the most rapidly 
growing indications for LT. 
NAFLD PATIENTS ON THE WAITLIST 
FOR LIVER TRANSPLANTATION
Every CLF patient has unique characteristics and needs 
an individual approach in the context of LT, and the 
same individual approach is necessary for patients who 
have NASH. The risk factors for poor postoperative 
and long-term outcomes are age the presence of MetS 
components (especially T2DM and obesity), coronary 
artery disease (CAD) and chronic kidney disease (CKD). 
Patients who have NASH on the waitlist often have 
several or all of these risk factors. For NASH patients 
on the waiting list there are two problems: patient 
comorbidities and lower MELD than other etiologies of 
CLD[28].
First, NAFLD is the liver manifestation of MetS and 
NAFLD patients on the LT waiting list frequently have 
one or more components of MetS. They are often obese 
and have T2DM, hypertension and hyperlipidemia. 
In addition, NASH recipients are older than recipients 
who have a different CLD[28]. According to Wong et al[10] 
compared to patients who had an alcoholic, viral or 
alcoholic/viral etiology of CLD who were on the waitlist 
for LT, patients with NASH had decreased renal function, 
were more obese and were more likely to have T2DM. 
There was higher morbidity and mortality in obese 
patients who underwent surgical procedures. However, 
in the context of obesity and LT, the results were not 
consistent. Several studies reported worse outcomes 
for obese patients, while other authors found similar 
risks and outcomes for both obese and non-obese 
patient groups[28]. For example, Leonard at al[29] had 
similar results for all body mass index (BMI) cate-
gories for early and late patients and graft survival. In 
contrast, La Mattina et al[30] found that obese patients 
had a longer operative time, intensive care unit length 
of stay, and more infectious and biliary complications 
that required intervention. There was no significant 
difference in patient or graft survival for overweight 
Class Ⅰ and obese Class Ⅲ recipients compared to 
normal weight recipients. However, patients who had 
Class Ⅱ obesity experienced decreased patient and 
in the occurrence of HCV, ALD and NAFLD/NASH as 
indications for liver transplantation. They demonstrated 
that active HCV infection decreased as an indication for 
LT after DAA use. Subsequently, there was a decrease 
in the incidence of cirrhosis due to HCV in the larger 
population with CLD[16]. In contrast, among patients 
who were on the waiting list and LT recipients, NAFLD 
became more common. Another interesting finding 
from this study was that the incidence of ALD as an 
indication for LT increased more than NASH[16]. A 
retrospective study by Cholankeril et al[17] had similar 
findings after analyzing the UNOS/OPTN database from 
2003 to 2014. The authors discovered that the number 
of LT that is secondary to NASH increased by 162% 
from 2003 to 2014, while the number of LT secondary 
to HCV increased by 33%, and the number of LT 
secondary to ALD increased by 55%[17].
Recently, there has been a trend of an increased 
incidence of HCC in developed countries, and according 
to the literature, this increase is most likely due to an 
increased incidence of MetS[8,18]. The large Bridge study 
included 18031 HCC patients from 2005-2012. NAFLD 
was one of the major risk factors for HCC development, 
and NAFLD was the cause of chronic liver disease for 
approximately 10%-12% of patients[19,20]. Similarly, 
a recently published US study found that HCC as a 
consequence of NASH is the fastest growing indication 
for LT. The authors of this study reported that NASH 
related HCC as an indication for LT had an almost 
fourfold increase since 2002; on the other hand, HCC 
that results from HCV, doubled[13,21].
In the context of LT and NAFLD, it is concerning 
that a recent discovery found that HCC may appear 
in NAFLD patients who do not have liver cirrhosis or 
advanced liver fibrosis[8]. Mittal et al[22] published data 
on 13% of patients who had HCC and, at the time 
of diagnosis, did not have cirrhosis. The primary risk 
factor for developing HCC was the presence of NAFLD 
or MetS. In addition, in a study by a group of German 
authors, 41.7% of the patients with NAFLD/NASH HCC 
previously had no diagnosis of cirrhosis[23]. Similar 
findings were also reported by other authors[24,25].
Another concerning issue in the context of NASH and 
LT is the increase in the incidence of NAFLD in children 
and young adults (up to age 40). Feldstein et al[26] 
analyzed long-term outcomes and survival for children 
who had NAFLD. In this study, children who had NAFLD 
had a 13.8-fold higher risk of requiring LT or dying than 
the general population of the same age and sex[26]. 
Recently, Alkhouri et al[27] analyzed LT in children and 
young adults and the frequency of NASH as an indicator 
for LT. They found an increased incidence of NASH as 
an indicator for LT in young patients. More than 100 
recipients had LT before they were 34 years old, while 
most patients received their liver transplant closer to 
the age of 40 years[27].
Current guidelines do not recommend regular 
screenings for HCC in NAFLD patients who have no 
Mikolasevic I et al . NAFLD and liver transplantation
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allograft survival[29]. Not long ago, Conzen et al[31] 
found that morbid obesity had negative effects on long-
term outcomes regardless of the short-term results. 
In other words, there were no differences in operative 
time, intensive care unit or hospital length of stay or 
perioperative complications. Over 3 years, recipient 
and graft survival rates were similar across groups. 
Compared to the non-obese, recipients who had a BMI 
> 40 kg/m2 experienced a significantly decreased 5-year 
graft (49.0% vs 75.8%; p < 0.02) and recipient (51.3% 
vs 78.8%; p < 0.01) survival. Although between group 
comparisons is difficult given the different endpoints 
and BMIs between cohorts, in general, obese patients 
have increased complication rates and more resource 
utilization compared to non-obese recipients[19]. Given 
the increase in the incidence of overweight patients 
and MetS, we can expect an increase in the number 
of patients with NASH cirrhosis or HCC in NASH with 
high BMI who are on the transplant list in the future. 
In addition, the bariatric surgery (BS) methods will 
become more important in the context of treating 
obesity for the morbid obesity of NASH patients. There 
are promising research findings for BS in these patients. 
There are studies with a small number of patients who 
were experiencing LT and some form of BS[28]. For 
example, Heimbach et al[32] conducted a small study 
that combined LT with a sleeve gastrectomy, which 
resulted in significant weight loss for patients who were 
not successful with medical treatment. In addition, 
there were less post-LT metabolic complications[32].
Recently, 11 studies with 56 patients were analyzed 
in a systematic review[33]. Two studies reported that 
BS had been previously performed, while two studies 
performed it during and seven after LT. The most 
common procedure was the sleeve gastrectomy, while 
the Roux-en-Y gastric bypass, biliopancreatic diversion 
and gastric banding were performed in a slightly smaller 
number of patients. There was no mortality in the early 
postoperative period, with a 5.3% rate during the first 
postoperative year. The reoperation rate was 12.2%. 
Although mortality and morbidity are higher in this 
population, the authors agreed that BS appears to be 
possible[33].
In the future, there is a need for randomized studies 
to determine which patients on the transplant list will 
benefit from BS, the optimal time for BS (before, during 
or after LT) and the optimal type of BS. It is important 
to note that patients who have decompensated cirrhosis 
have a higher mortality rate after BS than those who 
have compensated cirrhosis or no chronic liver disease; 
thus, it is extremely important to optimize the time at 
which patients should undergo BS[28,34]. Future studies 
are also needed to demonstrate the long-term impact of 
BS on liver transplant recipients and graft outcomes[28]. 
Patients who have NASH and are on the waitlist for 
LT often have T2DM. Pre-transplant T2DM is a strong 
predictor of poor short and long-term patient and graft 
survival. The poor outcomes are primarily attributed 
to an increased incidence of postoperative infectious 
complications, CVD complications and kidney failure[35,36]. 
A recent study by Hoehn et al[36] indicated that recipients 
with pre-LT diabetes in the post-transplant period had 
a longer hospital length of stay, as well as higher peri-
transplant mortality and 30-d readmission rates. In 
addition, they are less likely to be discharged home 
and, finally, have lower graft and patient survival than 
recipients who do not have diabetes[36]. 
For the above observations, NASH recipients often 
have one or more and often multiple, comorbidities that 
significantly affect the CVD risk in these patients so CVD 
risk assessment in NAFLD recipients is one of the largest 
problems in context of LT. According to the guidelines 
from European Association for the Study of the Liver 
(EASL), aside from obligatory electrocardiogram and 
transthoracic echocardiography in pre-LT evaluation, 
further tests need to be done to exclude asymptomatic 
ischemic heart disease (cardiopulmonary exercise test 
and if necessary in high risk patients even coronary 
angiography)[37]. Wray et al[38] showed that if coronary 
artery disease (CAD) is treated effectively before LT, 
survival after LT is not significantly different between 
patients with or without obstructive CAD.
Currently, many authors agree that NAFLD is a liver 
as well as a multisystem disease that is commonly 
associated with CVD, T2DM and CKD[39]. Research has 
shown that NAFLD is associated with an increased risk 
of adverse CVD events[39-42]. It is not clear whether 
the risk for CVD is increased in NAFLD patients due 
to coexisting dysmetabolic traits or whether NAFLD is 
actively involved in the pathogenesis of cardiovascular 
disease[35,39]. Previous research has shown that patients 
who have NASH related ESLD, compared to other 
ESLD recipients, have a higher CVD risk, specifically 
soon after LT[36]. For example, Patel et al[43] analyzed 
420 ESLD patients that were assessed for LT: 125 had 
alcohol-related ESLD, and 295 had non-alcohol-related 
ESLD. The incidence of severe coronary artery disease 
(CAD) (defined by a > 70% diameter stenosis) was 
13% in the non-alcohol-related ESLD group (p < 0.005) 
and 2% in the alcohol-related ESLD group. Moreover, 
a retrospective cohort study by Vanwagner et al[44] 
analyzed 242 LT recipients (127 alcohol-related and 115 
NASH ESLD) at a post-transplant follow-up that was 
more than 12 mo. After controlling for recipient sex, 
age, smoking status, CVD, pre-transplant diabetes and 
the presence of MetS, the multivariate analyses shown 
that NASH patients were more likely to have a CVD 
event than alcohol-related ESLD recipients in the first 
year after LT. Most of the (70%) CVD events occurred 
in the perioperative period, and 50% of the mortality 
was related to the occurrence of a CVD event. However, 
there were no differences between the two groups in 
graft and patient survival[44].
According to these observations, it is important to 
screen all LT candidates for the presence of MeS and/or 
risk of CVD, especially when they have NASH related 
ESLD. Prospective studies are needed to answer these 
important questions and to provide a foundation for a 
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standardized approach to CVD risk assessment in the 
population of LT candidates[35].
An additional risk factor in the context of NAFLD is 
CKD, which is also a well-known CVD risk factor. Previous 
research has shown that patients who have NAFLD 
have a higher prevalence of CKD than patients who do 
not have NAFLD[39,45]. A recent study by Singal et al[46] 
confirmed that the most rapidly increasing indication for 
simultaneous liver-kidney (SLK) transplantation is NASH, 
which has poor renal outcomes. The authors of this 
study found that SLK significantly increased in the group 
of patients who had NASH and cryptogenic cirrhosis 
compared to ESLD that was related to other etiologies; 
the incidence increased from 6.3% from 2002 to 2003 
to 19.2% from 2010 to 2011. Five-year LT recipient and 
graft survival rates did not differ between recipients who 
had NASH or cryptogenic cirrhosis and those with other 
etiologies of ESLD. On the other hand, in the group of 
patients who had NASH and cryptogenic cirrhosis, the 
risks for a kidney graft loss was more than 1.5-fold 
higher. Compared to recipients who had ESLD that was 
related to alcohol, primary biliary cirrhosis or primary 
sclerosing cholangitis, the estimated glomerular filtration 
rate remained lower in in the recipients who had NASH/
cryptogenic ESLD[46].
When selecting LT candidates who have NASH, 
the largest challenge is merging these risk factors into 
one risk stratification tool. As such, a multi-disciplinary 
approach is needed to evaluate these candidates for 
LT.
Importantly, in the context of NASH related ESLD 
candidates for LT, there is an association between NASH 
and macrovascular venous thrombosis, especially 
portal vein thrombosis (PVT)[47]. In NASH patients who 
have cirrhosis, there is a hypercoagulable state that 
is characterized by increased levels of plasminogen 
activator inhibitor 1 and factor VIII, while anticoagulant 
levels of protein C are decreased in patients with 
cirrhosis due to NASH[47,48]. Stine et al[47] recently 
analyzed 33368 patients who have ESLD and received 
LT. Of these, 2096 (6.3%) patients had PVT and 
12% had NASH. A comparison of NASH related ESLD 
recipients with all other causes of cirrhosis revealed 
a higher prevalence of PVT, with 10.1% in the first 
group versus 6% for those without NASH (p < 0.001). 
NASH cirrhosis was the strongest risk factor that was 
independently related to PVT in a multivariable analysis. 
Although the clinical significance of PVT is not entirely 
clear, especially whether anticoagulant therapy should 
be used, individual studies have shown that PVT is 
associated with adverse outcomes in patients who have 
ESLD. Specifically, several authors have shown that PVT 
is associated with increased pre- and post-transplant 
mortality, as well as with technical challenges during the 
transplant procedure[47,49-51]. However, the connections 
among NASH and PVT with hypercoagulation state is 
an ever-expanding field of clinical research. Additional 
studies on this topic are needed because there will be a 
significantly higher number of patients who have ESLD 
due to NASH on the waitlist for LT in the future, and, 
possibly, a higher number of thromboembolic incidents 
in these patients, including PVT[47].
The second important issue in the context of NASH 
patients who are on the waitlist for LT is competition for 
liver allograft allocations due to a lower MELD than other 
etiologies of CLD. According to current reports, patients 
who have ESLD due to NASH and are on the waitlist for 
LT have better liver functioning and, consequently, lower 
MELD scores than other etiologies of liver cirrhosis. In 
addition, these patients have a slower progression of 
disease[18,28]. A study by O´Leary et al[52] compared the 
data for 218 patients who had NASH or cryptogenic 
cirrhosis (CC) and underwent LT between 2002 and 
2008, with 646 patients transplanted due to ESLD that 
resulted from HCV infection. Among patients who had 
NASH and CC, the median progression rate was 1.3 
MELD points per year, and in the group of patients who 
had HCV, it was 3.2 MELD points per year (p = 0.003)[52]. 
Compared to patients who have HCV-related cirrhosis, 
patients who had NASH/CC and MELD scores ≤ 15 had 
fewer chances of receiving LT. They also had a higher 
risk of dying and a two-times higher risk of rejection 
or removal from the waiting list due to no suitable 
operative procedure given the progression of the liver 
disease or complications with their comorbidities. 
However, all patients who had MELD scores that were 
higher than 15 were more likely to undergo LT despite 
their diagnosis[52]. According to the findings from 
this study, the aggressive treatment of associated 
comorbidities is highly important; the components of 
MetS (hypertension, T2DM, dyslipidemia and obesity) 
in patients who have low MELD scores can prevent the 
progression of their comorbid conditions that are likely 
to cause death or make the patient ineligible for LT[52]. In 
addition, a recent study by Wong et al[10] demonstrated 
that NASH patients, compared to HCV, ALD or HCV/ALD 
related ESLD, are less likely to receive LT in the first 90 
days on the waitlist. Another interesting finding from 
this study is that the one-year waiting list survival rate 
for ESDL patients due to NASH declined over the study 
period from 42.8% to 25.6%. In contrast, patients who 
had HCC due to NASH, compared to other etiologies of 
CLD with HCC, had better liver functioning and lower 
MELD or Child Pugh scores[18]. Taken together, these 
data suggest that LT candidates who have NAFLD/NASH 
related ESLD pose a specific challenge for the transpl-
ant community given their longer LT waiting time and 
associated comorbidities.
NAFLD IN DONOR LIVERS
Another challenge in the context of NASH in LT is liver 
allograft steatosis. Specifically, the epidemic increase in 
the incidence of NAFLD/NASH in the general population 
has a direct influence on the increased prevalence of 
NAFLD in deceased and living liver donors[11,28]. Based 
on predictions that the prevalence of MetS and its liver 
manifestations (i.e., NAFLD) will increase in coming 
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years, we can expect more donors with NAFLD/NASH. 
We know that the availability of donor livers depends 
the success of the LT program. There is a global lack of 
organs for transplantation, as the gap between patient 
“demand” and organ “supply” continues to grow[53]. As 
such, transplant centers must use livers from “extended 
criteria donors” (ECD). Due to higher risk for ischemia- 
reperfusion injury (IRI), the severity of liver steatosis is 
related to a higher risk for graft failure and/or impaired 
graft function. Upon reperfusion, steatosis can cause 
microcirculatory and cellular changes in the liver graft 
that can lead to hepatocyte necrosis. In contrast, there 
is an impaired potential for regenerating steatotic 
livers[11,28,54-56]. For donors whose livers are more than 
60% steatotic, this is almost a universal scenario; 
however, for those who are 30%-60% steatotic, there 
are controversial outcomes for donor livers[11,28,54,55]. For 
example, Spitzer et al[57] have shown that macrovesicular 
steatosis is an independent risk factor for graft survival. 
Recently, Chu et al[55] published a systematic review that 
analyzed 34 articles. The authors found that steatotic 
grafts that were > 60% were associated with an 
increased risk for poor graft functioning, while grafts that 
were > 30% of steatosis were related to decreased graft 
survival rates[55]. The lack of a standardized definition for 
primary non-functioning or impaired primary functioning 
and descriptions of the types of steatosis in research are 
the primary flaw in these studies. With more common 
utilization of ECD livers, using liver allografts that have 
less than 30% macrovesicular steatosis should be 
harmless for recipients[11,28,54,55].
There is no standardized procedure for estimating 
liver steatosis in potential donors; thus, evaluation 
procedures of liver grafts for steatosis and the use of 
steatotic livers for LT differ across transplant centers. 
Although some centers perform liver biopsies in high 
risk donors (abnormal liver tests, associated comorbi-
dities, diabetes mellitus, high body mass index, older 
age, hepatitis B or C infections), others evaluate all 
potential donors[11,54,58]. Liver biopsies are the “gold 
standard” for detecting and assessing for steatosis. As 
an invasive procedure, liver biopsies can damage the 
organ. Moreover, it can only sample 1/50000 of the 
liver; thus, there is the potential for significant sampling 
error and limits in the numbers and sizes of biopsies. In 
addition, there is significant inter-observer variability for 
evaluating the degree of steatosis. These disadvantages 
place the procedure in the “silver standard” position; 
however, because there is not a better referential 
method, biopsy is still viewed as the “gold standard”. 
Additionally, waiting for the liver biopsy results before 
deciding whether to accept the organ extends the 
cold ischemia time. Therefore, there is a need for 
simple, rapid and non-invasive methods for detecting 
steatosis in the donor[11,54,59]. Imaging methods such as 
ultrasonography, magnetic resonance and computed 
tomography are not sensitive or exact in detecting 
steatosis that is below 30%. Moreover, these methods 
cannot differentiate between micro-vesicular and macro-
vesicular steatosis[11,54,58,59]. Recently, elastographic 
methods have been intensively investigated in the 
context of the noninvasive assessment of liver steatosis 
and fibrosis. One of the most investigated is transient 
elastography (TE), with a controlled attenuation 
parameter (CAP). In the context of donor livers, Mancia 
et al[60] examined 23 brain-dead potential donors. 
They analyzed TE with its CAP and reviewed liver stiff-
ness measurements (LSM) to objectively assess liver 
steatosis and fibrosis. The implementation of TE with 
both CAP and LSM demonstrated good preoperative 
assessment for the histological condition and stage of 
the donors’ liver steatosis[60]. Recently, Hong et al[61] 
investigated the usefulness of CAP as a screening tool 
for detecting liver steatosis in living donor livers. The 
author found that area under the receiver operator 
characteristic curve for diagnosing steatosis (≥ S2) 
with CAP was 0.88, with a cutoff value of 276 dB/m. 
According to the findings from this study, CAP could 
be an adequate noninvasive method for excluding 
significant liver steatosis (> 33%) in liver donors[61]. 
There is a need for more research on using TE with CAP 
to evaluate steatosis and fibrosis in possible donors. 
A higher incidence of NAFLD/NASH in the general 
population will lead to a higher risk of donors who have 
NAFLD, which will influence on number of suitable 
organs from both living and deceased donors. Given 
the increasing incidence of NAFLD, we will face an even 
greater lack of LT organs or will be forced to accept liver 
donors that have NAFLD/NASH and are lower quality, 
with a high risk for poor outcomes after LT[15,54].
LIVER TRANSPLANTATION OUTCOMES 
FOR NAFLD PATIENTS
Although patients who are transplanted because of 
ESLD that is related to NASH have several comorbidities 
and are often older in age, post-LT survival is 
comparable to other etiologies of ESLD. Multiple, single-
center studies of survival in ESLD related to NASH 
patients who had an LT, as well as several large studies 
were conducted over the years[28]. The studies that 
assess post-LT outcomes for NASH are summarized in 
Table 1.
One of the first studies to report outcomes for NASH 
patients after LT was conducted by Malik et al[62] and 
was published almost 10 years ago. This was the first 
study to analyze patients who had a histopathological 
diagnosis of NASH in the context of LT. The authors 
analyzed the post-LT outcomes for 98 NASH patients 
vs 686 with other etiologies, including primary biliary 
cirrhosis/primary sclerosing cholangitis (PBC/PSC), 
ALD, HCV and cryptogenic cirrhosis (CC). In 71 NASH 
patients, the diagnosis of NASH was based on pre-LT 
biopsies, and in 27 patients, the diagnosis of NASH was 
confirmed upon explant. The five-year survival rates 
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after the LT were similar between the patients who 
were transplanted for NASH and the patients who were 
transplanted for other etiologies of ESLD. On the other 
hand, there was a tendency for higher mortality soon 
after the LT (30-d mortality was 6.1%), and one year 
after the LT (21.4%). NASH patients who were older 
(≥ 60 years), obese (BMI > 30 kg/m2), and had pre-
LT hypertension and pre-LT T2DM had a higher risk for 
poor post-LT outcomes. Another important finding was 
that infection was the most common cause of death 
in the NASH patients compared to the controls[62]. In 
2009, Bhagat et al[63] published a retrospective study 
that reported the post-LT outcomes for the NASH 
and ALD groups of patients who underwent LT. The 
authors found that overall survival and death rates 
due to CVD events was higher in the NASH group, but 
this difference was not significant. Interestingly, acute 
rejection crises and recurrent steatohepatitis occurred 
significantly more often in the NASH group but did not 
lead to higher rates of re-transplantation[63]. Two years 
later, Barritt et al[64] published another retrospective, 
but small, study. The primary finding of this study was 
that NASH, as an indication for LT, was the independent 
factor that influenced early post-LT mortality[28,64]. In 
2012, Agopian et al[65] published a large, single-center 
study and found that the frequency of ESLD due to 
NASH as an indication for LT increased from 3% in 
2002 to 19% in 2011. They reported that patients who 
were transplanted for NASH had a longer operative 
time, more operative blood loss and a longer post-
LT length of stay. On the other hand, recipient and 
graft survival rates at one, three and five years were 
comparable to patients who were transplanted for other 
causes of ESLD. The predictors of poor outcomes for 
the recipient and its graft were pre-LT obesity and pre-
LT hemodialysis[28,65]. Early postoperative mortality 
due to infections and CVD events in the recipients who 
were transplanted for ESLD due to NASH was reported 
in Kennedy et al[66]. This study also highlighted that an 
older age (> 60 years), pre-LT obesity, hypertension 
and T2DM were associated with lower five-year survival 
rates after LT. However, the overall survival rates at 
one, three and five years were comparable to other 
etiologies of ESLD[28,66]. VanWagner et al[44] discovered 
that NASH recipients had an increased risk for adverse 
CVD events in the first year after the LT compared 
to recipients who had ALD. The presence of MetS 
before LT was the most important risk factor[42]. One 
of the largest national US studies that addressed the 
outcomes of LT for ESLD due to NASH was published 
by Afazali et al[67]. The author used the UNOS database 
and analyzed 1810 LT recipients who had ESLD due to 
NASH, 3843 recipients who had ESLD due to CC, and 
48085 recipients who had ESLD due to other etiologies 
of ESLD. The author reported an increased proportion of 
LTs for NASH patients; from 1.2% in 1997-2003 to 7.4% 
in 2010. NASH and CC recipients had good survival 
rates that were comparable to other etiologies of CLD. 
Consistent with other studies, there was a higher rate of 
early mortality in the NASH patients. In addition, in line 
with earlier, small studies, an older age, pre-LT T2DM, 
obesity and pre-LT hypertension were risk factors 
Table 1  Post liver transplantation outcomes for patients who have nonalcoholic fatty liver disease
Ref. Study size NASH group survival (%) Non-NASH group survival (%) Study period
Malik et al[62] 98 NASH 30-d - 93.9 30-d - 94.4-98.0 1997-2008
686 Non-NASH group (PBC/PSC, ALD, HCV, CC) 1-yr - 79.6 1-yr - 81.6-87.2
5-yr - 72.4 5-yr - 65.3-80.6
Bhagat et al[63] 71 NASH 1-yr - 82 1-yr - 92 1997-2007
83 ALD 5-yr - 75 5-yr - 86
9-yr - 62 9-yr - 76
Barritt et al[64] 21 NAFLD 30-d - 80.9 30-d - 97 2004-2007
83 Non-NAFLD (ALD, HCV, HBV, PBC/PSC, AIH) 1-yr - 76.2 1-yr - 89.5
3-yr - 76.2 3-yr - 83.5
Agopian et al[65] 144 NASH 90-d - 90 90-d - 90-96 1993-2011
1150 Non-NASH (HBV, HCV, ALD, CC, PBC/PSC) 1-yr - 84 1-yr - 79-87
5-yr - 75 5-yr - 54-70
Kennedy et al[66] 129 NASH 1-yr - 90 1-yr - 92 1999-2009
775 Non-NASH - etiologies not defined 3-yr - 88 3-yr - 86
5-yr - 85 5-yr - 80
Park et al[67] 71 NASH 1-yr - 78 1-yr - 87 1998-2008
472 Non-NASH 2-yr - 78 2-yrs - 85
Vanwagner et al[44] 115 NASH 1-yr - 81.3 1-yr - 88.1 1993-2010
127 ALD 3-yr - 73.3 3-yr - 85.3
5-yr - 60.3 5-yr - 68.8
Afazali et al[68] 1810 NASH 1-yr - 87.6 Variable 1997-2010
3843 CC 3-yr - 82.2
48.085 Non-NASH 5-yr - 76.7
Charlton et al[14] 1959 NASH 1-yr - 84 1-yr - 87 2001-2009
33822 Non-NASH 3-yr - 78 3-yr - 78
NAFLD: Nonalcoholic fatty liver disease; ALD: Alcoholic liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus; CC: Cryptogenic cirrhosis; PBC: 
Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis.
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for higher mortality rates in the first year after LT[68]. 
Another large national US study that used the SRTR 
database and was performed by Charlaton et al[14] had 
similar findings.
Finally, a meta-analysis that was published four 
years ago by Wang et al[69] showed that similar number 
of patients with and without NASH survived for 1, 3, 
and 5 years after LT; however, those who had NASH 
were more likely to die due to adverse CVD events or 
sepsis[69].
In most studies, patients who were transplanted 
for ESLD related to NASH had very good survival rates. 
One-year survival rates were between 85% and 90%, 
while five-year survival ranged from 70% to 80% in 
most studies. In addition, patients who underwent 
LT due to NASH-related ESLD had almost the same 
outcomes as other etiologies of CLD. It is interesting 
that NASH recipients, despite multiple comorbidities, 
have survival comparable to that of other etiologies of 
CLD. One possible explanations is that the rate of NASH 
and cirrhosis recurrence is lower than the recurrence 
of HBV or HCV[35,68]. Another consideration is that these 
patients undergo a very extensive pre-transplantation 
screening for risk evaluation and cardiovascular 
status, thus; those who have significant cardiovascular 
morbidity are excluded from the transplant list. 
However, according to the results, overall survival after 
LT is good in the NASH recipient group, and a higher 
incidence of post LT CVD events are noted in NASH 
recipients. However, infections (sepsis) were observed 
more frequently in this group of recipients. When 
selecting NASH patients for LT, there is a need for more 
attention and careful consideration combined with the 
radical management of sepsis and CVD complications 
after LT[11,68,69].
NONALCOHOLIC FATTY LIVER DISEASE 
AFTER LIVER TRANSPLANTATION
Progress in surgical techniques for transplant surgery, 
as well as the development of immunosuppressive 
therapy, led to decreased early post-LT mortality and, 
consequently, to improved survival rates after LT, with 
a 90% survival rate at the first year and a survival rate 
of more than 70% five years after LT. The development 
of metabolic comorbidities, combined with this higher 
post-LT survival, contributes to morbidity and mortality 
rates. Subsequently, the focus of research is changing 
to long-term complications, such as CVD[70-72]. CVD 
can be initiated with every insulin resistance (IR) 
associated component of MetS. Furthermore, the 
clinical features and prevalence of MetS, such as T2DM, 
hypertension, rapid weight gain and dyslipidemia, 
often deteriorate in the post-LT period based on 
transplant specific factors, for example, adverse events 
in immunosuppression. They are also related to the 
recipients’ morbidity and mortality[70,72]. For metabolic 
balance, for hyperglycemia, weight gain, hypertension 
and hyperlipidemia, immunosuppressant drugs, such as 
corticosteroids, calcineurin inhibitors (CNIs) (cyclosporine 
(CSA), tacrolimus (TAC)) and mammalian target of 
rapamycin inhibitors (mTORs) (such as sirolimus (SIR) 
and everolimus), have a crucial role. Corticosteroids 
stimulate gluconeogenesis. CNI stimulates the post-
LT occurrence of new-onset diabetes (NOD) that is 
more likely related to TAC use compared to CSA. CNI 
also initiates the development of post-LT hypertension, 
and it appears that CSA is highly related to the 
development of hypertension after LT. For dyslipidemia, 
CSA has a higher risk of causing dyslipidemia than 
TAC. Finally, for dyslipidemia, mTORs are the most 
unfavorable immunosuppressive drugs. These groups 
of immunosuppressive drugs may, to an extent, 
affect the development of CVD through metabolic 
complications[70-72]. Most transplanted patients become 
obese after LT, with the highest increase in weight 
occurring after the first six months, as well as one 
and three years after LT[70,72,73]. Of the liver recipients, 
10%-64% develop T2DM, 45%-69% experience 
hyperlipidemia, and approximately 50%-100% develop 
hypertension after LT[70-72]. Thus, a significant number 
of liver recipients met the criteria for MetS, which 
indicates that these patients have a higher risk for 
CVD[70-72]. Based on the literature, MetS is present in 
approximately 50%-60% of transplant patients[71]. 
Therefore, MetS is an important post transplantation 
problem. Because NAFLD is a liver manifestation of 
MetS, it is not surprising that both recurrent and de 
novo NAFLD can be found after LT[70-72]. According to 
the abovementioned observations, MetS components 
(i.e., NAFLD risk factors) may persist or worsen after 
LT due to the high incidence of MetS after LT. NAFLD 
can affect the post-LT course in two ways. First, post-
transplant NAFLD can develop as a recurrence of a pre-
LT condition, and can progress to cirrhosis and lead to 
ESLD when re-transplantation is necessary. Second, 
due to the high incidence of MetS components after 
LT, NAFLD can also occur de novo and complicate 
the course of the recipients who are transplanted for 
other etiologies of CLD[28,70-72,74]. More than 25 years 
ago, Burke et al[75] were the first to describe recurrent 
NAFLD, and authors from San Francisco, CA, United 
States, reported the first case series of de novo NAFLD 
in 2003[76].
According to the literature, recurrent NAFLD is a 
relatively common diagnosis after LT. Across reports, 
the rates of recurring steatosis and NASH range from 
30%-100%[28]. For example, Bhagat et al[70] found that 
33% of patients who were transplanted due to NASH 
cirrhosis had steatohepatitis in biopsy specimens 
during the first six months after the LT. On the other 
hand, none of these patients developed cirrhosis or 
required re-transplantation during the 10-year follow-
up period[70]. A group of Dallas authors[77] conducted a 
retrospective study and analyzed post-LT outcomes for 
257 patients undergoing LT for CC or NASH cirrhosis. 
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After comparing patients who had NASH/CC with 
patients who underwent LT due to other etiologies 
of CLD, they found that more NASH/CC patients 
developed graft steatosis at one, two, five and 10 
years post-LT (8.2%, 13.6%, 24.9% and 32.9%) than 
those who were transplanted for other etiologies (3.1%, 
5.9%, 9.6% and 10%). Of the 257 NASH/CC patients, 
13 developed NASH, and 5% and 10% developed 
bridging fibrosis or cirrhosis after 5 and 10 years. This 
outcome was more common in patients who had NASH 
than in those who developed steatosis per se or had no 
fat (3%). The survival rate during the 10-year follow-
up was similar for patients who underwent LT for CC or 
NASH or LT for other indications. However, the cause of 
death differed between those two groups, as the NASH 
group had more adverse CVD events[77]. Moreover, 
Dureja et al[78] evaluated 88 liver transplant recipients 
that underwent LT due to NAFLD-related cirrhosis from 
1993 to 2007. There was recurrent NAFLD in 34 liver 
transplants, isolated steatosis in 9 and steatohepatitis 
in 25 recipients, while there was advanced fibrosis in 3 
recipients. The survival rate after LT was not affected 
by NAFLD recurrence, but a higher number of CVD 
and infectious complications were reported in this 
group[78]. Recently, Sourianarayanane et al[79] published 
a retrospective study and analyzed data from NASH 
and ALD transplant recipients between 2001 and 
2006. The authors found that NASH recipients had a 
higher incidence of steatosis and inflammation after 
LT; however, the progression of fibrosis was slower in 
NASH than in ALD recipients[79]. Recently, Bhati et al[80] 
analyzed 103 patients who were transplanted for NASH 
in whom TE and liver biopsies were used to assess 
steatosis and fibrosis. Of 103 total patients, 56 had 
TE, while 34 had a liver biopsy. Implementing TE with 
CAP demonstrated that 87.5% of the patients who had 
steatosis also had recurrent NAFLD. Most patients had 
LSM with no fibrosis (42.9%) or F1-F2 fibrosis (30.4%). 
Overall, 26.8% of the patients had advanced fibrosis, 
while 5.4% developed cirrhosis. Of the patients who 
underwent a liver biopsy, 88.2% had recurrent NAFLD, 
while almost half (41.2%) had NASH. Bridging fibrosis 
was noted in 20.6% of patients; however, none of the 
patients had cirrhosis. In most patients, cancer (25%) 
or infectious complications (25%) were the cause 
of death in combination with CVD (21.9%). Graft 
cirrhosis only caused 9% of the deaths. According to 
this recent study, recurrent NAFLD commonly occurs 
after LT (88% of all patients), while nearly a quarter 
of the patients developed advanced fibrosis[80]. An 
interesting observation was published on the genetic 
predisposition for NAFLD recurrence. The presence of 
the rs738409-G allele of the Patatin-like phospholipase 
in LT recipients is an independent risk factor for post-
LT steatosis, as well as obesity and T2DM[72,81].
Most research that investigates the prevalence of 
recurrent NASH in post-LT patients have shown that the 
incidence of recurrent NASH is between 20% and 40%, 
while the incidence largely depends on NASH detection 
methods, including liver enzymes, imaging techniques 
or liver biopsies. Most of the studies that investigated 
the incidence of recurrent NASH were retrospective, 
without a standard post-LT interval biopsy protocol. 
In addition, the histological criteria that was used for 
defining the diagnosis of recurrent NAFLD varied among 
published studies[74,81,82]. Therefore, there is a need for 
prospective studies that show the actual incidence and 
progression for recurrent NAFLD after LT. Also, it is not 
clear is NAFLD a primitive process, to which follows 
MetS, or is it just the opposite. Further research on this 
topic are needed. 
A recently published study investigated the incidence 
of NASH in children and young adults as indications for 
LT in addition to post-LT patients and graft outcomes. 
Alkhouri et al[27] found that approximately 4% (13) 
of patients who were transplanted for NASH cirrhosis 
needed re-transplantation due to NASH recurrence. 
Based on the literature, approximately one-third of 
patients who were transplanted for non-NASH indications 
developed IR and MetS (risk factors for NAFLD) in the 
three years post-LT. As such, researchers have attended 
to understanding the development of de novo NAFLD in 
recipients who underwent LT for indications other than 
NASH[11]. Ten years ago, Seo et al[83] retrospectively 
analyzed data from 68 recipients who experienced LT 
due to ESLD that was related to non-NASH indications. 
They reported that 18% of the recipients developed de 
novo NAFLD, while 9% developed de novo NASH. The 
data analysis showed that the utilization of angiotensin-
converting enzyme inhibitors (ACE-I) was related to 
a decreased risk for developing NAFLD after LT. In 
contrast, an increased BMI of more than 10% after LT 
was a risk factor for NAFLD after LT[83]. The observation 
related to the protective effect of ACE-I in the context of 
de novo NAFLD after LT is interesting given preliminary 
findings that renin-angiotensin (RAAS) inhibitors have 
a beneficial effect on the regression of NAFLD in non-
transplanted patients[84]. Recently, we have shown that 
using the RAAS inhibitor is associated with a lower rate 
of NAFLD as defined by TE with CAP in the population 
of renal transplant recipients[85]. However, additional 
research is needed on the benefits of using RAAS 
inhibitors to prevent the occurrence or progression 
of NAFLD in post-LT patients[85]. A few years ago, 
Dumortier et al[86] published a retrospective study 
that analyzed the prevalence of NAFLD in post-LT liver 
biopsies from 421 recipients who were transplanted 
for non-NASH indications. Histological evidence of 
steatosis occurred in 131 (31.1%) patients; and 53% 
had grade 1, 31% grade 2 and 16% grade 3 steatosis. 
Interestingly, 51.1% of those with steatosis had normal 
liver enzymes. There was perisinusoidal fibrosis in 
38 patients (29.0%), while 5 patients (3.8%) were 
diagnosed with NASH. In contrast, there was cirrhosis 
or extensive fibrosis in 2.25% of recipients at the 
end of the follow-up. The authors noted that post-LT 
obesity, tacrolimus-based regimen, hyperlipidemia, 
hypertension, diabetes mellitus, and alcoholic cirrhosis 
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were the primary indications for the LT and, combined 
with pre-transplant liver graft steatosis, were risk factors 
for steatosis after transplantation[86]. This is the first 
study that showed an association between the presence 
of steatosis in the donor liver and the development 
of new NAFLD after the LT[28,86]. Recently, Kim et al[87] 
showed that preexisting donor graft steatosis is asso-
ciated with a threefold increased risk for developing 
post-LT NAFLD (OR = 3.147, p = 0.022). Although the 
impact of donor steatosis on graft and patient outcomes 
remains an insufficiently explored area, the growing 
incidence of NAFLD in general population indicates an 
urgent need for further investigations on this topic[13].
Another interesting topic in the context of NAFLD 
after LT is the difference between recurrent and de 
novo NAFLD after LT. Vallin et al[88] published the first 
longitudinal study four years ago with a small number 
of patients. The authors analyzed the characteristics 
of 91 patients who experienced LT between 2000 
and 2010. They compared biological, clinical, and 
histological markers for patients who had recurrent 
NAFLD and patients who had de novo NAFLD. During 
the study, 91 patients were given a diagnosis of post-
LT NAFLD: 11 cases were classified as recurrent 
NAFLD, and 80 cases were classified as de novo 
NAFLD. There were no differences in sex, age and 
the prevalence of obesity, hypercholesterolemia or 
hypertension. However, in patients with recurrent 
NAFLD, there was a higher prevalence of diabetes 
mellitus (100% vs 37.5%). Severe fibrosis (stage 
3 or 4) and steatohepatitis at 5 years had a higher 
incidence in patients who had recurrent NAFLD than in 
patients with de novo NAFLD [71.4% vs 12.5% (p < 
0.01) and 71.4% vs 17.2% (p < 0.01), respectively]. 
Additionally, after 1 year, NAFLD was diagnosed in 
67% of patients who had de novo NAFLD, while it was 
present in all patients who had recurrent NAFLD. For 
the liver biopsy, steatosis disappeared in 18 patients 
(22.5%) who had de novo NAFLD and in no patients 
who had recurrent NAFLD[88]. Although this was a 
small study, it is important to note that recurrent 
and de novo NAFLD after LT are different entities and 
recurrent NAFLD appears to be a more severe and 
irreversible condition with an earlier onset[88]. 
Although many drugs have been examined for 
treating NAFLD/NASH in the general population, there 
is still no efficient therapy for NAFLD. Thus, there are no 
studies that examine treatment options for preventing 
or treating the development or recurrence of NAFLD/
NASH after LT. Because NAFLD is a liver manifestation 
of MetS, we need to prevent and treat all MetS 
components in post-LT patients. Given the metabolic 
effects of immunosuppressive drugs that are used in 
liver transplant recipients, this can often be challenging. 
For now, we can attempt to prevent and manage 
hypertension, dyslipidemia, diabetes and obesity, as well 
as individualize immunosuppressive therapy in post-LT 
patients to prevent NAFLD recurrence/development and 
CVD complications in all recipients[28,70,72].
NAFLD AND CHRONIC KIDNEY DISEASE 
AFTER LIVER TRANSPLANTATION
CKD is another important area and potential challenge 
in the context of NAFLD and LT. The survival of the 
graft and patient as well as the success of LT directly 
depends on kidney functions. Unfortunately, it is almost 
impossible to prevent the development of CKD after 
LT. For the occurrence of CKD after LT, there are three 
primary risk factors: pre-LT kidney disease, using 
immunosuppressive drugs and recipient comorbidities. 
Several authors reported that a risk factor for the 
development and progression of CVD and CKD is 
NAFLD[70,72,89-91]. Musso et al[89] performed a meta-
analysis that included 33 studies 4 years ago. The 
study showed that NAFLD was related to an increased 
incidence and prevalence of CKD. There is a close 
relation between NAFLD and risk factors for CVD and 
CKD, which makes it difficult to determine whether 
NAFLD is only a risk marker for CVD and/or CKD or 
a causal factor[71,90,91]. Park et al[67] reported similar 
results for NASH patients who were on the waitlist. 
Patients who had ESLD due to NASH on the waiting 
list had significantly higher levels of serum creatinine 
than patients who had other etiologies of ESLD, 
despite similar MELD scores[67]. Moreover, NASH is also 
important in the context of CKD for the post-LT setting. 
The first study that highlighted this association was 
by Houlihan et al[91]. They demonstrated that patients 
who underwent LT for ESLD related to NASH developed 
worse renal functioning than patients who had ESLD 
due to other etiologies. Compared to non-NASH 
patients, three months after LT, NASH patients had a 
significantly lower estimated glomerular filtration rate 
(eGFR). During the next two years 31.2% of the NASH 
patients (15/48) developed stage IIIb CKD, which only 
occurred in 8.3% of the non-NASH patients (4/48)[91]. 
Three years later, Fussner et al[92] reported that female 
gender and NASH were independent predictors of ≥ 
stage 3 CKD development at 5 years post-LT. 
Given the increase in the incidence of ESLD due 
to NASH, and based on the MELD allocation system, 
which favors LT for patients with higher creatinine 
(kidney injury), the incidence of CKD after LT is also 
likely to increase. In order to prevent pre- and post-LT 
CKD, more effective methods of treatment are needed, 
such as, delayed usage of CNIs or immunosuppres-
sive protocols without CNIs which may be effective 
way for saving kidney function after LT. Therefore, 
immunosuppressive protocols should be considered in 
the context of LT and NASH, and more pro-perspective 
studies are needed on this topic[28,91,93].
CONCLUSION
NAFLD/NASH is a challenging and multisystem disease 
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that has a high socioeconomic impact. NAFLD/NASH, 
as a primary cause of macrovesicular steatosis, has 
several impacts on LT; on patients on the waiting list 
for transplant, on post-transplant setting as well as 
on organ donors. Current data indicate a new trend in 
the area of CLD. Because of the increased incidence of 
T2DM and obesity, i.e., the growing incidence of MetS, 
there is a parallel rise in the HCC incidence[13,19,25,54,94]. 
Consequently, NASH cirrhosis and HCC due to NASH will 
soon become the major indications for LT. Importantly, 
recent investigations and observations indicate that 
HCC can occur in patients who have NAFLD without 
liver cirrhosis. Because screening for HCC is not a part 
of standard approach for a patient with NAFLD without 
cirrhosis, HCC is often diagnosed in advanced stages. 
One of the primary goals of health care practitioners 
should be to increase awareness of NAFLD/NASH and to 
develop and conduct useful screening programs for this 
increasing patient population[13,19,25,54]. 
An increased incidence of MetS and, consequently, 
NAFLD/NASH effects the demand for LT and the supply 
of available donors. Thus, we can expect that there 
will be a higher number of steatotic livers for LT in the 
future. The lack of organs is a global problem and could 
result in one of two possible scenarios. We will either 
choose low quality organs that have a greater risk for 
post-transplantation complications and, consequently, a 
higher risk for worse outcome of LT. The second option 
is that we will decrease steatotic livers but the time on 
the waiting list will become longer and, consequently, 
there will be an increase in wait-list mortality. To develop 
appropriate method for optimizing the allocation of 
steatotic grafts prior to LT, research needs to examine 
procedures to protect it from IRI or primary graft non-
functioning and to expand the pool of available donors. 
Moreover, future research should identify new non-
invasive diagnostic methods for the exact detection and 
quantification of steatosis in donor organs. In addition, 
more data on other potential risk factors that are 
associated with the development of steatotic livers is 
necessary[28,54]. 
There are two problems with keeping NASH patients 
on the waiting list: their comorbidities and lower MELD 
scores compared to other etiologies of CLD. These 
patients often have different metabolic risk factors and 
coexisting CVD and/or CKD, which makes managing 
these patients complicated and demanding. As such, 
there is a need for more detailed and personalized 
screening and evaluations of NAFLD/NASH patients, 
particularly for assessing CVD. According to available 
research, there are no universal guidelines or clear 
recommendations for the optimal screening method 
for CVD in patients who have NASH related ESLD and 
are candidates for LT. We need new prospective studies 
that will answer this important question and provide a 
basis for a standardized approach to assessing CVD risk 
in this population of LT candidates[13,28,35] In addition, 
randomized studies are needed to determine which 
NASH patients on the transplant list will benefit from 
treatment with BS, the optimal time for BS (before LT, 
during LT, after LT) and the type of BS to apply[28,34]. 
Future research is also needed to demonstrate the long-
term impact of BS on LT recipients[28].
Patients who have ESLD due to NASH and un-
derwent LT have similar post-transplant outcomes as 
other etiologies of CLD[35,68]. However, according to 
research, the total survival rates after LT are good, but 
NASH recipients have a higher incidence of CVD events 
after LT. Interestingly, infections (sepsis) were also more 
frequently observed in this group of recipients. The 
NASH LT recipients should be viewed as population at 
high risk for CVD, thus, there is a need for more studies 
on how to follow and treat these patients[11,68,69].
The prevalence of MetS clinical features, such as 
T2DM, hypertension, rapid weight gain and dyslipidemia, 
are often higher in the period after LT, are frequently 
caused by transplant specific factors, including immu-
nosuppression, and can be valuable predictors of re-
cipients’ morbidity and mortality. Immunosuppressant 
drugs, such as corticosteroids, CNIs and mTORs, 
have a specific role in metabolic balance and favor 
hyperglycemia, weight gain, hypertension and hyper-
lipidemia. These groups of immunosuppressive drugs 
may, to an extent, contribute to the formation of CVD 
by affecting metabolic complications[70,72]. Most studies 
that examine the prevalence of recurrent NASH in 
the post-LT setting have shown that the incidence of 
recurrent NASH is between 20% and 40%, but the 
incidence largely depends on NASH detection methods, 
such as liver enzymes, imaging techniques or liver 
biopsies. Most of the studies that investigated the 
incidence of recurrent NASH have been retrospective, 
without the standard Post-LT interval biopsy protocol. 
In addition, the histological criteria that are used for the 
diagnosis of recurrent NAFLD varied in the published 
studies[74,81]. Therefore, prospective studies with well-
defined biopsy protocols are needed to show the actual 
incidence and progression of recurrent NAFLD after 
LT. According to the literature, in one-third of patients 
who were transplanted for non-NASH indications, IR 
and MetS developed within three years post-LT. As 
such, more research has focused on understanding 
the development of de novo NAFLD in recipients who 
underwent LT for indications other than NASH[11]. 
Another interesting topic in the context of NAFLD after 
LT is the difference between recurrent and de novo 
NAFLD after LT. Although the results from previous 
studies were conducted with a small number of 
patients, it is important to note that recurrent NAFLD 
and de novo NAFLD after LT are different entities and 
that recurrent NAFLD appears to be much more severe 
and irreversible and has an earlier onset[88]. 
Preliminary data indicated that preexisting donor 
graft steatosis is associated with a threefold increase 
in the risk for developing post-LT NAFLD. However, the 
influence of donor steatosis on the graft and patient 
outcomes has been minimally explored, and given the 
growing incidence of NAFLD in the general population, 
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there is an urgent need for further investigations on 
this topic[13,87].
NASH is important in the context of CKD and in the 
post-LT setting. Preliminary data outline that NASH is an 
independent predictor of ≥ stage 3 CKD development 
after LT[91,92]. Given the increase in the incidence of 
ESLD due to NASH, there is also likely to be an increase 
in the incidence of CKD after LT. The transplant society 
will have to identify a more useful approach to these 
patients to prevent pre- and post-LT CKD. The delayed 
use of CNIs or immunosuppressive protocols without 
CNIs may be an effective way for saving kidney function 
after LT. Therefore, immunosuppressive protocols should 
be considered in the context of LT and NASH, and more 
pro-perspective studies are needed on this topic[28,91,93].
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